NYSE:COGlobal Cord Blood Stock Price, Forecast & News

Global Cord Blood's stock was trading at $4.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CO stock has decreased by 26.5% and is now trading at $2.99. View which stocks have been most impacted by Coronavirus.

Global Cord Blood is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for Global Cord Blood.

Global Cord Blood Corp (NYSE:CO) released its earnings results on Tuesday, June, 26th. The medical research company reported $0.04 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.13 by $0.09. The medical research company had revenue of $37.14 million for the quarter. Global Cord Blood had a return on equity of 12.64% and a net margin of 38.57%. View Global Cord Blood's earnings history.

News coverage about CO stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Global Cord Blood earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Global Cord Blood.

Global Cord Blood saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 26,500 shares, a decrease of 30.6% from the June 15th total of 38,200 shares. Based on an average trading volume of 178,200 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company's shares are sold short. View Global Cord Blood's Current Options Chain.

Some companies that are related to Global Cord Blood include HL Acquisitions (LPRO), NYSE:FEAC (FEAC), AdaptHealth (AHCO), GS ACQUISITION /SH CL A (GSAH), Collier Creek (CCH), Bain Capital Specialty Finance (BCSF), HAYMAKER ACQUIS/SH CL A (HYAC), FORUM MERGER II/SH CL A (FMCI), CF Finance Acquisition (CFFA), Leisure Acquisition (NEBU), Crescent Capital BDC (CCAP), Gores Holdings III (GRSH), Hennessy Capital (HCAC), Thunder Bridge Acquisition II (SSPK) and Schultze Special Purpose Acquisition (ARYA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Cord Blood investors own include AbbVie (ABBV), Fate Therapeutics (FATE), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Rite Aid (RAD), Rigel Pharmaceuticals (RIGL), Spero Therapeutics (SPRO), Galectin Therapeutics (GALT), Gilead Sciences (GILD) and Intel (INTC).

Global Cord Blood trades on the New York Stock Exchange (NYSE) under the ticker symbol "CO."

Shares of CO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CO stock can currently be purchased for approximately $2.99.

Global Cord Blood has a market capitalization of $363.43 million and generates $172.50 million in revenue each year. Global Cord Blood employs 1,261 workers across the globe.

The official website for Global Cord Blood is www.globalcordbloodcorp.com.

Global Cord Blood's mailing address is 48 FL. BANK OF CHINA TOWER 1 GARDEN ROAD, HONG KONG K3, . The medical research company can be reached via phone at 852-3605-8180 or via email at [email protected]